OpenAI Unveils $200/Month ChatGPT Pro Plan for Power Users

Key Highlights:

• OpenAI launches a $200/month "ChatGPT Pro" plan as part of its December product updates.
• The plan offers unlimited access to OpenAI's most advanced models, including o1, o1-mini, GPT-4o, and Advanced Voice.
• ChatGPT Pro provides enhanced performance with the new o1 pro mode, designed for complex tasks like math, science, and coding.
• OpenAI also announced a special grant for medical researchers to use ChatGPT Pro in their work.

OpenAI has launched a new premium ChatGPT Pro plan, priced at $200 per month, offering unlimited access to its most powerful AI models. The plan includes OpenAI’s cutting-edge o1 model, as well as o1-mini, GPT-4o, and Advanced Voice features. One standout feature of this subscription is the o1 pro mode, designed to provide deeper reasoning and more accurate answers, especially for tough tasks like solving complex math problems, writing code, or conducting scientific research.

As part of OpenAI's special "12 Days of Shipmas" launch event in December 2024, the company is targeting advanced users and businesses who need the highest-level AI capabilities. This new plan builds on the success of the ChatGPT Plus and ChatGPT Team subscriptions but offers a significant leap in performance. The $200/month ChatGPT Pro is nearly ten times the price of the previous premium plan, but OpenAI believes it will be worthwhile for users who need high-quality, reliable answers for professional or research purposes.

With this new tier, OpenAI is aiming to offer enhanced productivity and solve more difficult problems, including better performance in coding, math, and even visual reasoning thanks to the new image upload feature. However, this plan comes with a hefty price tag compared to competitors, and its target audience is power users, small businesses, or enterprise customers with niche needs.

OpenAI also announced a positive initiative to support medical research, with 10 grants of ChatGPT Pro being provided to researchers at top U.S. institutions to help them analyze complex biomedical data.